During the course of this study, cabozantinib, a TKI with TAM and SPLIT family receptor targets in common with sitravatinib, as well as FLT3, ROS1 and TIE-2, was approved for patients with VEGFR-TKI-refractory RCC, further supporting the rationale for sitravatinib in this setting [20]. Here, FLT3 is linked to renal cell carcinoma.